Flaws in Monsanto’s Safety Assessment of Roundup Ready Soybeans

Third World Network Biosafety Information Service, 28 July 2003.

Monsanto has maintained that there is no difference between GM soybeans and its conventional strains. But according to a Japanese scientist, whose report is attached below, safety tests conducted by Monsanto are riddled with flaws that include: testing of proteins not derived from the GM plant; soybeans used for tests were not produced with Roundup, therefore the data obtained with such samples may not be valid to guarantee the safety of soybean that human and animals consume in real life; insufficient feeding experiments; and intentional neglect of “inappropriate” data which have a bearing on the final conclusions.

Bron:  OCA: Flaws in Monsanto’s Safety Assessment of Roundup Ready Soybeans

Recent Evidence Confirms Risks of Horizontal Gene Transfer

Recent Evidence Confirms Risks of Horizontal Gene Transfer 

I-SIS Contribution to ACNFP/Food Standards Agency Open Meeting 13 November 2002

Citaat:
Horizontal gene transfer is one of the most serious, if not the most serious hazard of transgenic technology. I have been drawing our regulators’ attention to it at least since 1996 [1], when there was already sufficient evidence to suggest that transgenic DNA in GM crops and products can spread by being taken up directly by viruses and bacteria as well as plant and animals cells.

Dr. Mae-Wan Ho, Institute of Science in Society, PO Box 32097, London NW1 0XR

Predicted Hazard of Gene Therapie a Reality

Predicted Hazard of Gene Therapy A Reality

I-SIS was almost a lone voice warning of cancer from foreign genes inserting into the genome in ‘gene therapy’ and other exposures to transgenic DNA. Regrettably, this has now become reality.
Dr. Mae-Wan Ho calls for a comprehensive review of gene therapy and other transgenic technologies, for they carry similar risks.

The French team that made news in 2000 treating children with severe combined immune deficiency (SCID) had to call a halt to the gene therapy trial. One of the ten children treated has developed what looks like leukaemia.
(bron: Source: Science, News of the Week, 4 October 2002)